<DOC>
	<DOCNO>NCT00567047</DOCNO>
	<brief_summary>This study evaluate pharmacokinetics vildagliptin metabolite patient mild , moderate severe renal impairment healthy volunteer .</brief_summary>
	<brief_title>Pharmacokinetic Study Vildagliptin Patients With Renal Impairment</brief_title>
	<detailed_description />
	<mesh_term>Vildagliptin</mesh_term>
	<criteria>Inclusion Criteria ( general ) : Men woman ( age 18 85 year ) Participants must nonfertile use medically approve birth control method . Additional information regard requirement available screen Body mass index ( BMI ) ≤42 kg/m2 ( inclusive ) Inclusion Criteria ( renal insufficient patient ) : Patients mild , moderate , severe kidney impairment . Please consult participate physician regard definition level severity . Patients diabetes must treat standard antidiabetic therapy ( diet exercise , stable dose sulfonylurea , insulin , metiglinides ) agree continue study duration Inclusion Criteria ( healthy subject ) : No current significant medical condition determine history physical . Serum creatinine calculate creatinine clearance ( CrCl ) &gt; 80 ml/min . Matched renal impair patient study age ( ±5 year ) , sex weight ( ±10 % BMI ) Vital sign guide follow range : oral body temperature 35.037.2 °C systolic blood pressure , 100140 mm Hg diastolic blood pressure , 60110 mm Hg pulse rate , 4590 bpm Exclusion criterion : Pregnant lactate female . A history type 1 diabetes , diabetes result pancreatic injury , secondary form diabetes , acute metabolic diabetic complication ( eg , ketoacidosis hyperosmolar state ( coma ) ) Subjects enrol previous vildagliptin study DPP 4 inhibitor study within six month History renal transplant immunosuppressant therapy Acute infection may affect blood glucose control medical condition may interfere interpretation efficacy safety data study Any preexist history diabetic ulcer Any follow within past 6 month : myocardial infarction ( MI ) , coronary artery bypass surgery percutaneous coronary intervention , unstable angina stroke Any follow electrocardiogram ( ECG ) abnormality : Torsades de pointes , sustain clinically relevant ventricular tachycardia ventricular fibrillation , second degree atrioventricular ( AV ) block ( Mobitz 1 2 ) , third degree AV block , prolong QTc ( &gt; 500 m ) Malignancy include leukemia lymphoma within last 5 year . Liver disease cirrhosis positive hepatitis B C. Any alcohol relate hepatic disease . Patients undergo method dialysis Use concomitant medication Significant laboratory abnormality specify protocol History active substance abuse ( include alcohol ) within past 2 year . Smokers ( i.e. , 10 cigarette per day ) History hypersensitivity study drug drug similar chemical structure Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2009</verification_date>
</DOC>